[Study on the prediction of AR-V7 and CTC circulation in patients with metastatic, castration-resistant prostate cancer (mCRPC) : Correlation between common clinical outcome parameters (rPFS, OS), CTC changes, and AR-V7 status (androgen receptor splice variant 7) in patients with mCRPC on first-line therapy with abiraterone acetate (STAR-V7)-study AP 96/17 of the AUO]

MeSH terms

• Abiraterone Acetate / therapeutic use*
• Drug Resistance, Neoplasm
• Humans
• Male
• Neoplastic Cells, Circulating
• Phenylthiohydantoin / therapeutic use
• Prostatic Neoplasms, Castration-Resistant / drug therapy*
• Prostatic Neoplasms, Castration-Resistant / pathology
• Receptors, Androgen / analysis
• Receptors, Androgen / blood*